i3 Expands Partnership With Eli Lilly and Company
Pharmaceutical services company i3 announced that global pharmaceutical firm Eli Lilly and Company (NYSE: LLY) is transferring select activities to support its U.S. clinical trials, including the areas of U.S. medical writing and biostatistical services, to i3 as part of Lilly’s continuing effort to transform its business in order to speed improved outcomes to individual patients. This move marks a significant expansion of the business relationship between the two organizations since Lilly transferred the majority of its U.S. data management operations to i3 in 2008.
This agreement builds on i3’s steady growth in the area of functional service provision (FSP), having composed and deployed successful FSP teams throughout the industry since 1999.
Life science companies have found that partnering with service providers in functional areas, such as information sciences—including data management, medical writing, and biostatistical services—enhances efficiencies, improves quality, and reduces costs.
“i3, with an established presence on the north side of Indianapolis, has proved itself as a partner capable of consistently delivering high-quality work within our agreed-upon performance metrics,” said Aarti Shah, Ph.D., vice president statistics and advanced analytics hub, Eli Lilly and Company.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Using Patient Reported Outcomes in Dermatology Trials
April 25th 2024In part 3 of this video interview with ACT editor Andy Studna, Melissa Mooney, director, eCOA sales engineering, IQVIA sheds light on the unique challenges of dermatology trials and how clinical outcome assessments can be implemented in them.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
